

Supplementary Material

Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16

Authors

Jacob P. Thyssen¹, Marjolein de Bruin-Weller², Antonio Costanzo^{3,4}, Susanne Grond⁵, Christopher Schuster^{5,6}, Chunyuan Liu⁷, Maria Jose Rueda⁵, Yun-Fei Chen⁵, Andreas Pinter⁸, Thomas Bieber^{9,10}

¹ Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark

² National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, The Netherlands

³ Dermatology, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

⁴ Dermatology, Humanitas Research Hospital, Rozzano, Milan, Italy

⁵ Eli Lilly and Company, Indianapolis, IN, USA

⁶ Department of Dermatology, Medical University of Vienna, Vienna, Austria

⁷ Tigermed-BDM Inc, Somerset, NJ, USA

⁸ Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany

⁹ Department of Dermatology and Allergy, University Hospital, Bonn, Germany

¹⁰ Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland

Corresponding Author: Jacob Thyssen

Email address: jacob.pontoppidan.thyssen@region.dk

Supplementary Table 1

Outcome at Week 16	Accuracy	Sensitivity	Specificity	Positive Predicted Value	Negative Predicted Value
EASI75	0.6667	0.5849	0.7414	0.6739	0.6615
EASI75 or Itch NRS $\geq$4-point improvement	0.6036	0.5147	0.7442	0.7609	0.4923
Prediction accuracy table based on the BSA cut-off of 40% with baseline BSA >40 as a negative predictor and BSA $\leq$ 40 as a positive predictor. BSA=body surface area; EASI75= $\geq$ 75% improvement in Eczema Area and Severity Index; NRS=Numerical Rating Scale.					

Supplementary Table 2

	BSA 10-40%/ Itch NRS <7	BSA 10-40%/ Itch NRS $\geq$7	BSA >40%/ Itch NRS <7	BSA >40%/ Itch NRS $\geq$7
EASI75	N=53	N=29	N=76	N=86
Risk difference (95% CI) vs. PBO (%)	28.7	23.5	12.1	8.8
p-value vs. PBO	0.0002	0.0086	0.0113	0.0156
Itch NRS $\geq$4-point improvement	N=40	N=29	N=59	N=86
Risk difference (95% CI) vs. PBO (%)	10.3	27.0	14.2	12.5
p-value vs. PBO	0.1194	0.0036	0.0007	0.0022
BARI=baricitinib; BSA=body surface area; CI=confidence interval; EASI75= $\geq$ 75% improvement in Eczema Area and Severity Index; NRS=Numerical Rating Scale; PBO=placebo; n=number.				